Predict your next investment

Corporation
HEALTHCARE | Biotechnology
alexion.com

See what CB Insights has to offer

Investments

7

Portfolio Exits

2

Partners & Customers

10

Service Providers

3

About Alexion Pharmaceuticals

Alexion Pharmaceuticals is a biopharmaceutical company that combines science with a commitment to meeting the needs of patients living with severe, life-threatening, and often ultra-rare diseases.On July 21st, 2021, Alexion Pharmaceuticals was acquired by AstraZeneca at a valuation of $39000M.

Alexion Pharmaceuticals Headquarter Location

121 Seaport Boulevard

Boston, Massachusetts, 02210,

United States

+1 475 230 2596

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Alexion Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Alexion Pharmaceuticals in 1 Expert Collection, including Synthetic Biology.

S

Synthetic Biology

382 items

Alexion Pharmaceuticals Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Alexion Pharmaceuticals Rank

Latest Alexion Pharmaceuticals News

Novartis Has a Big Pile of Cash and Investors Are Demanding Action

Nov 18, 2021

11:22 AM IST, 18 Nov 2021 10:30 AM IST, 18 Nov 2021 11:22 AM IST, 18 Nov 2021 Save (Bloomberg) -- Switzerland’s two major pharmaceutical companies reside in the same sleepy city, Basel. Until recently, Novartis AG even owned a large chunk of Roche Holding AG, located within walking distance in a pair of gleaming white towers on the River Rhine. (Bloomberg) -- Switzerland’s two major pharmaceutical companies reside in the same sleepy city, Basel. Until recently, Novartis AG even owned a large chunk of Roche Holding AG, located within walking distance in a pair of gleaming white towers on the River Rhine. The highest skyscrapers in Switzerland, Roche’s imposing headquarters stand in stark contrast to the low-slung buildings grouped around a park-like campus that Novartis calls home on the other bank of the river. Lately, the two drugmakers have also diverged in other ways. While Novartis grapples with convincing investors of its pipeline of drugs and integrating a series of acquisitions, Roche has benefited from a record number of potential new treatments in late-stage development and strong demand for Covid-19 tests. Roche shares have climbed 20% this year, compared with a 9% drop for Novartis. Almost four years after taking the reins, Novartis Chief Executive Officer Vas Narasimhan is under growing pressure to reshape the pharma giant and make some shrewd moves. The urgency to act has only grown with the sale of a $21 billion stake in Roche this month that has given Novartis the financial firepower for a transformational deal. Buying a biotech company is one option, with Alnylam Pharmaceuticals Inc. -- a company with a market value in excess of $20 billion -- a prime potential target, according to people with knowledge of the matter, who spoke on condition of anonymity because the discussions are private. Novartis and Narasimhan, 45, could use a spark. Some of the drugs that were supposed to drive growth have failed in clinical trials, run into safety issues or been delayed. Among the setbacks are canakinumab, a would-be lung cancer drug that failed in trials this year, and a new version of Zolgensma, a gene therapy for children that’s up against competition from a Roche drug. The company declined to comment on potential acquisitions, or make its CEO available for an interview for this story. “You want the pipeline story -- you want to see where future growth will come from,” said Stefan Schneider, a Vontobel analyst in Zurich who advises investors hold Novartis shares. “You look at it as an investor and say, ‘We spent all that money to get a pipeline story on the table, but I don’t see it, yet.’” Narasimhan, a Novartis veteran, has already orchestrated a massive overhaul. The decision to end the two-decade investment in Roche and a potential spinoff or sale of the Sandoz generic-drug unit unveiled last month cap a series of strategic moves to sharpen the focus on cutting-edge medicines and break with the diversification of the past. If Narasimhan opts to sell Sandoz, he’d gain even more ammunition -- as much as $50 billion -- to pursue deals. “He’s basically removing what one might argue are hedge and safety measures and doubling down on innovation,” said John Rountree, a managing partner at London-based pharmaceutical consulting firm Novasecta. “That’s what investors want. They don’t want all of this distraction.” Disposal Investors are eagerly awaiting Narasimhan’s next moves after he ditched a stake in a consumer-health venture and spun off the Alcon eye-care unit in recent years. Other drug companies, including GlaxoSmithKline Plc, are making similar bets on therapies that could have a profound impact on both patients and profits while shedding assets that aren’t at the heart of their mission. Johnson & Johnson reinforced the point last week, announcing plans to separate the consumer division. The Roche disposal triggered speculation Novartis could snap up promising gene therapies, cancer treatments and other medicines. Alnylam, known for turning a Nobel Prize-winning concept called RNA interference, or RNAi, into approved treatments for rare genetic conditions, is one possibility. Vertex Pharmaceuticals Inc., Intellia Therapeutics Inc., Biogen Inc., Incyte Corp. and BioMarin Pharmaceutical Inc. are among a range of other companies seen as potential targets. “Management could elect to deploy most of the proceeds on a single large acquisition with late-stage clinical or marketed drugs,” which could improve the narrative around the stock, Jefferies analysts including Peter Welford wrote in a report. Sandoz opens up further possibilities. A spin-off could dilute Novartis shareholders, as the business is likely to trade at a lower multiple than the parent, according to people familiar with the discussions. While the parent company may prefer a straightforward sale, the unit’s growth prospects and a lack of buyers with sufficient firepower are possible hurdles. Novartis has said keeping the unit is also an option. It’s not that Narasimhan hasn’t already shown his dealmaking credentials. The drugmaker gained gene therapy Zolgensma through the $8.7 billion purchase of AveXis in 2018 and picked up Endocyte , a developer of cancer treatments, the same year. In 2019, Novartis agreed to buy Medicines Co. and heart drug inclisiran for $9.7 billion. Narasimhan said in a 2019 interview that he wanted to consistently spend the equivalent of about 5% of Novartis’s market value on deals each year. That’s about $10 billion today. With or without a Sandoz sale, additional deals are a tricky proposition. Four of Narasimhan’s last five acquisitions haven’t yet lived up to investors’ expectations, and because the company needs growth fast, it will continue to face high price tags for the next deals, Vontobel’s Schneider said. By contrast, a robust pipeline allows Roche to concentrate on earlier-stage deals that are cheaper. Novartis could also invest the Roche proceeds into research or development efforts -- or technology and artificial intelligence projects -- already underway internally. Novartis has likely been overshadowed by developers of successful or highly promising Covid vaccines and therapies, John Tsai, Novartis’s head of global drug development, said in an interview. Novartis sold its vaccines business several years ago, and its experimental Covid therapies haven’t panned out yet. Attractive assets in a vast pipeline targeting a range of other diseases are being overlooked, Tsai said. “The external world is undervaluing our mid-stage and late-stage pipeline significantly,” he said. Dismantling an Empire Yet some investors are anxious about the pace of a transformation that was set in motion years ago. Former chief Daniel Vasella oversaw the 1996 merger of Sandoz and Ciba-Geigy that created Novartis, a transaction that ranked as one of the largest combinations in the industry. Later, he bought the Roche shares, acquired a U.S. vaccine manufacturer for $7.5 billion and invested $50 billion into Alcon. Vasella’s departure as chairman in 2013 led some investors to speculate that the company would unwind some of the deals he had engineered. Now, almost nine years later, Novartis is on the cusp of a new chapter, led by an engaging chief who shunned his predecessor’s quiet corner office in favor of a seat out in the open, has vowed to “reimagine” medicine and moved to “un-boss” the pharma behemoth and its more than 100,000 employees. Although massive deals look less likely, Narasimhan could pull off a transaction similar to AstraZeneca Plc’s move into rare diseases with its late 2020 purchase of Alexion Pharmaceuticals Inc. for $39 billion, Novasecta’s Rountree said. said. That could give Novartis shareholders something to cheer. “Novartis is sort of plowing on with its strategy and for some investors that’s less exciting,” he said. “Investors aren’t necessarily seeing Novartis in that innovative way yet.” ©2021 Bloomberg L.P.

Alexion Pharmaceuticals Investments

7 Investments

Alexion Pharmaceuticals has made 7 investments. Their latest investment was in Caelum Biosciences as part of their Corporate Minority on January 1, 2019.

CBI Logo

Alexion Pharmaceuticals Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

1/31/2019

Corporate Minority

Caelum Biosciences

$30M

Yes

1

6/11/2018

Partnership

Subscribe to see more

$99M

Subscribe to see more

10

8/24/2016

Series F

Subscribe to see more

$99M

Subscribe to see more

10

3/3/2015

Partnership

Subscribe to see more

$99M

Subscribe to see more

10

12/19/2014

Series E

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/31/2019

6/11/2018

8/24/2016

3/3/2015

12/19/2014

Round

Corporate Minority

Partnership

Series F

Partnership

Series E

Company

Caelum Biosciences

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$30M

$99M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

10

10

10

10

Alexion Pharmaceuticals Portfolio Exits

2 Portfolio Exits

Alexion Pharmaceuticals has 2 portfolio exits. Their latest portfolio exit was Moderna Therapeutics on December 07, 2018.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/7/2018

IPO

$991

4

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

Date

12/7/2018

00/00/0000

Exit

IPO

Subscribe to see more

Companies

Subscribe to see more

Valuation

$991

$991

Acquirer

Subscribe to see more

Sources

4

10

Alexion Pharmaceuticals Acquisitions

8 Acquisitions

Alexion Pharmaceuticals acquired 8 companies. Their latest acquisition was Caelum Biosciences on September 29, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

9/29/2021

Corporate Minority

$991

$39.91M

Acquired

6

5/5/2020

IPO

Subscribe to see more

$991

$99M

Subscribe to see more

10

10/16/2019

PIPE - II

Subscribe to see more

$991

$99M

Subscribe to see more

10

9/26/2018

Series B

Subscribe to see more

$991

$99M

Subscribe to see more

10

4/11/2018

Series B

Subscribe to see more

$991

$99M

Subscribe to see more

10

Date

9/29/2021

5/5/2020

10/16/2019

9/26/2018

4/11/2018

Investment Stage

Corporate Minority

IPO

PIPE - II

Series B

Series B

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

$991

$991

Total Funding

$39.91M

$99M

$99M

$99M

$99M

Note

Acquired

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

6

10

10

10

10

Alexion Pharmaceuticals Partners & Customers

10 Partners and customers

Alexion Pharmaceuticals has 10 strategic partners and customers. Alexion Pharmaceuticals recently partnered with Genomenon on September 9, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

9/20/2021

Vendor

Genomenon

United States

Genomenon, Alexion Pharmaceuticals Team on Rare Disease Dx

NEW YORK -- Genomenon said Monday that it is collaborating with Alexion Pharmaceuticals to provide genetic testing laboratories with data to help diagnose patients with rare diseases .

3

12/16/2019

Licensor

Dicerna Pharmaceuticals

United States

Alexion Exercises Option for Two Additional GalXC™ RNAi Programs for Complement-Mediated Targets Under Collaboration With Dicerna™

The agreement provides Alexion Pharmaceuticals , Inc. with exclusive worldwide licenses and commercial rights to the GalXC RNAi molecules developed in the collaboration in exchange for development - and approval-related milestones , sales milestones and mid-single to low-double-digit royalties on future product sales .

2

10/14/2019

Licensor

Stealth BioTherapeutics

United States

Alexion partners on Stealth’s late-stage mitochondrial asset

The first stage of the partnership will be an assessment of Phase III clinical readouts , at which point Alexion Pharmaceuticals has the option to opt-in to the co-development and commercialization of Stealth BioTherapeutics 's lead asset .

2

9/9/2019

Licensor

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

9/9/2019

Licensor

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

9/20/2021

12/16/2019

10/14/2019

9/9/2019

9/9/2019

Type

Vendor

Licensor

Licensor

Licensor

Licensor

Business Partner

Genomenon

Dicerna Pharmaceuticals

Stealth BioTherapeutics

Country

United States

United States

United States

Subscribe to see more

Subscribe to see more

News Snippet

Genomenon, Alexion Pharmaceuticals Team on Rare Disease Dx

NEW YORK -- Genomenon said Monday that it is collaborating with Alexion Pharmaceuticals to provide genetic testing laboratories with data to help diagnose patients with rare diseases .

Alexion Exercises Option for Two Additional GalXC™ RNAi Programs for Complement-Mediated Targets Under Collaboration With Dicerna™

The agreement provides Alexion Pharmaceuticals , Inc. with exclusive worldwide licenses and commercial rights to the GalXC RNAi molecules developed in the collaboration in exchange for development - and approval-related milestones , sales milestones and mid-single to low-double-digit royalties on future product sales .

Alexion partners on Stealth’s late-stage mitochondrial asset

The first stage of the partnership will be an assessment of Phase III clinical readouts , at which point Alexion Pharmaceuticals has the option to opt-in to the co-development and commercialization of Stealth BioTherapeutics 's lead asset .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

3

2

2

10

10

Alexion Pharmaceuticals Service Providers

4 Service Providers

Alexion Pharmaceuticals has 4 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

Acq - P2P

Investment Bank

Financial Advisor

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Subscribe to see more

Associated Rounds

Acq - P2P

Subscribe to see more

Subscribe to see more

Provider Type

Investment Bank

Subscribe to see more

Subscribe to see more

Service Type

Financial Advisor

Subscribe to see more

Subscribe to see more

Partnership data by VentureSource

Alexion Pharmaceuticals Team

25 Team Members

Alexion Pharmaceuticals has 25 team members, including current Chief Financial Officer, Carsten Boess.

Name

Work History

Title

Status

Scott Rollins

Founder

Current

Stephen Squinto

Founder

Current

Carsten Boess

Chief Financial Officer

Current

Paul Firuta

Chief Operating Officer

Current

David Hallal

Chief Executive Officer, Chief Operating Officer, Chief Commercial Officer

Former

Name

Scott Rollins

Stephen Squinto

Carsten Boess

Paul Firuta

David Hallal

Work History

Title

Founder

Founder

Chief Financial Officer

Chief Operating Officer

Chief Executive Officer, Chief Operating Officer, Chief Commercial Officer

Status

Current

Current

Current

Current

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.